ACES Signs Landmark Agreement with BMRCL to Build 4G/5G-Ready Neutral Host Telecom Infrastructure Across Namma Metro
BANGALORE, India, July 17, 2025 /PRNewswire/ -- ACES India Private Limited, a…
Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025
- Presentations highlight clinically meaningful reductions in BMI in patients with acquired…
Youth lead the way as Milano Cortina 2026 embodies the new Italian spirit
26 June 2025 - With less than eight months to go until…
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025
SAN FRANCISCO and BOSTON, July 06, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics,…
IPO Bound Pace Digitek Limited Inaugurates BESS Manufacturing Facility in Bidadi, Karnataka
BENGALURU, India, July 3, 2025 /PRNewswire/ -- Pace Digitek Limited (Pace Digitek),…
AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer
PRESS RELEASE MASITINIB RECEIVES FDA AND EMA AUTHORIZATION FOR CONFIRMATORY PHASE 3…
Azentio appoints Harikrishnan Venkataramanan as President – ERP to spearhead next phase of innovation and growth
SINGAPORE, July 3, 2025 /PRNewswire/ -- Azentio Software ("Azentio"), a leading technology…
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
July 02, 2025 06:00 ET Â | Source: Instil Bio US phase 1…
Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy
July 02, 2025 03:00 ET Â | Source: Belite Bio, Inc -Â 500…
Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress
New FRONTIER5 data show that a direct switch to investigational Mim8 (denecimig)…